Table of Contents
Regulatory Issues in the Development of Drug Treatments for Various Psychiatric and Behavioral Disturbances Associated with Dementia Thomas Laughren, M.D. Team Leader, Psychiatric Drug Products Group Division of Neuropharmacological Drug Products FDA
FDA Recognition of Clinical Spectrum in the Dementias
BPSD as Useful Concept
|
Author: CDER USER
|